Global and China Stem Cell Industry Report, 2014-2017
  • Sep.2014
  • Hard Copy
  • USD $2,400
  • Pages:107
  • Single User License
    (PDF Unprintable)       
  • USD $2,250
  • Code: PQ012
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $3,500
  • Hard Copy + Single User License
  • USD $2,600
      

Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. Stem cell therapy can be applied to treatment of cardiovascular diseases, leukemia (a kind of hematological system disease), nervous system diseases, damage or lesion of liver, kidney and other parenchymal organs, etc..

Currently, cord blood bank is the fastest-growing and relatively mature market amid stem cell upstream sectors and even the whole industry chain. In 2005, there were 23 cord blood banks worldwide and in 2013 the figure exceeded 480. Global cord blood stem cell (CBSC) storage companies can be roughly divided into two categories: the ones running in a globalized business model, such as Cryo-Cell International and Esperite (formerly known as Cryo-Save Group), and the others giving priority to regional operation e.g. Zhongyuan Union Stem Cell Bioengineering (VCANBIO), Golden Meditech and LifeCell International. However, the companies mainly engaged in cord blood bank business are currently small in scale, only a few with more than 500,000 clients.

The stem cell technology and product research-oriented midstream sector is in its infancy, mostly concentrated in few countries like Europe, America and South Korea. At present, most companies in the industry chain are basically in the red for years running due to huge R&D costs. Nevertheless, attracted by the tremendous market potential in the area of stem cell therapy and enjoying the great encouragement from government policies (e.g. capital subsidy) and the capital support of significant cooperative partners, very few companies have dropped out.

Up to now, altogether 9 sorts of stem cell products have been approved worldwide, 3 of which are in the category of stem cell drugs developed by S. Korean companies, such as MEDIPOST’s adult stem cell drug CARTISTEM for osteoarthritis treatment and the stem cell product Prochymal (MEDIPOST obtained the product via acquiring the Therapeutics business of Osiris Therapeutics) direct at treating children suffering acute graft-versus-host disease (GVHD).

In the meantime, traditional pharmaceutical giants like Novartis are setting about quickly accessing the field through mergers and acquisitions. On Aug. 19, 2014, Novartis reached an acquisition agreement with Gamida Cell (a corporate dedicated to stem cell technology R&D and its application in stem cell transplantation for leukemia patients), which specified that Novartis spend USD35 million in acquiring 15% equity in the latter and win the option to take over the remaining equity in two years with USD165 million; in Sep. 2013, Novartis also entered a cooperation with Regenerex to jointly develop the hematopoietic stem cell platform FCRx of the latter.

干细胞 英文_副本.jpg


Global and China Stem Cell Industry Report, 2014-2017 highlights the followings:
20120114.gifClassification, application, industry chain definition, etc. of stem cells;
20120114.gifMajor enterprises, policies, upstream/midstream/downstream development and prospects, etc. of global stem cell industry;
20120114.gifPolicies, upstream/midstream/downstream development, etc. of China stem cell industry;
20120114.gifOperation, stem cell business, etc. of 6 upstream companies and 19 midstream/downstream companies worldwide.

1. Overview of Stem Cell Industry
1.1 Definition
1.2 Classification & Application
1.3 Industry Chain
1.4 Development Course

2. Global Stem Cell Industry Chain
2.1 Industry Chain Layout of Major Enterprises
2.2 Policy
2.3 Development
2.4 Upstream
2.5 Downstream
2.6 Prospect

3. China Stem Cell Industry Chain
3.1 Development Introduction
3.2 Policy Environment
3.3 Upstream
3.4 Midstream
3.5 Downstream

4. Upstream Enterprises
4.1 Cryo-Cell International
4.1.1 Profile
4.1.2 Operation
4.1.3 Cord Blood Business
4.2 Esperite
4.2.1 Profile
4.2.2 Operation
4.2.3 Revenue Structure
4.2.4 Stem Cell Business
4.3 Zhongyuan Union Stem Cell Bioengineering
4.3.1 Profile
4.3.2 Operation
4.3.3 Revenue Structure
4.3.4 Gross Margin
4.3.5 R&D and Investment
4.3.6 Stem Cell Business
4.3.7 Development Forecast
4.4 Golden Meditech
4.4.1 Profile
4.4.2 Operation
4.4.3 Revenue Structure
4.4.4 Profit
4.4.5 Cord Blood Business
4.4.6 Development Forecast
4.5 LifeCell International
4.5.1 Profile
4.5.2 Cord Blood Business
4.6 Cryosite
4.6.1 Profile
4.6.2 Operation
4.6.3 Revenue Structure
4.6.4 Stem Cell Business

5. Midstream and Downstream Enterprises
5.1 NeoStem
5.1.1 Profile
5.1.2 Operation
5.1.3 Revenue Structure
5.1.4 R&D
5.1.5 Stem Cell Business
5.2 Mesoblast
5.2.1 Profile
5.2.2 Operation
5.2.3 R&D and Investment
5.2.4 Stem Cell Business
5.3 MEDIPOST
5.3.1 Profile
5.3.2 Operation
5.3.3 Stem Cell Business
5.4 Beike Biotechnology
5.4.1 Profile
5.4.2 Stem Cell Business
5.5 Osiris Therapeutics
5.5.1 Profile
5.5.2 Operation
5.5.3 R&D
5.6 Orthofix International
5.6.1 Profile
5.6.2 Operation
5.6.3 Revenue Structure
5.6.4 R&D
5.6.5 Stem Cell Business
5.7 Cytori Therapeutics
5.7.1 Profile
5.7.2 Operation
5.7.3 R&D
5.8 Athersys
5.8.1 Profile
5.8.2 Operation
5.8.3 R&D
5.9 Pluristem Therapeutics
5.9.1 Profile
5.9.2 R&D
5.9.3 Recent News
5.10 StemCells
5.10.1 Profile
5.10.2 Operation
5.10.3 R&D
5.11 Advanced Cell Technology
5.11.1 Profile
5.11.2 Operation
5.11.3 R&D
5.12 Celgene
5.12.1 Profile
5.12.2 Operation
5.12.3 R&D
5.13 Vitro Biopharma
5.13.1 Profile
5.13.2 Operation
5.13.3 R&D
5.13.4 Stem Cell Business
5.14 Reneuron
5.14.1 Profile
5.14.2 Operation
5.14.3 R&D
5.15 Tigenix
5.15.1 Profile
5.15.2 Operation
5.15.3 R&D
5.16 Cellular Biomedicine Group, Inc. (CBMG)
5.16.1 Profile
5.16.2 Operation
5.16.3 R&D
5.16.4 Stem Cell Business
5.16.5 Business in China
5.17 Opexa Therapeutics
5.18 ZhongKeBiopharm
5.19 Cyagen Biosciences
Classification of Stem Cell 
Overview of Stem Cell Therapy Area (by Disease Type)
Advantages and Disadvantages of Stem Cell Therapy
Source and Application of Adult Stem Cells (by Type)
Stem Cell Industry Chain
Industry Chain Distribution of Major Global Stem Cell Enterprises
Global Authorized Stem Cell Products and Their Clinical Application
Major Products under Development, Therapeutic Area and Clinical Trial Stage of Global Stem Cell Therapy as of 2014H1
Global Stem Cell Market Size and YoY Growth, 2007-2013
Global Human Stem Cell Clinical Trials and Treatment Application Structure, 2013
Clinical Application of Global Stem Cell Technology (by Disease Type), 2013
Cord Blood Bank Distribution in Major Countries as of 2014H1
Cord Blood Application in Major Countries
Global Top 10 Death Causes (by Death Toll), 2012
Global Top 10 Death Causes (by Income Group), 2012
Global Top 10 Death Causes in Low-income Countries, 2012
Global Top 10 Death Causes in Low- and Middle-income Countries, 2012
Global Top 10 Death Causes in Middle- and High-income Countries, 2012
Global Top 10 Death Causes in High-income Countries, 2012
Global Stem Cell Application Prospect
Global Stem Cell Market Size and YoY Growth, 2014-2017E
Some Chinese Stem Cell Clinical Trial Drugs Approved by CFDA
China Stem Cell Industry Policies, 1999-2014
Major Enterprises and Their Stem Cell Business in China Upstream Stem Cell Industry
Major Enterprises and Their Stem Cell Business in China Midstream Stem Cell Industry 
China Stem Cell Medical Market Size and YoY Growth, 2007-2017E
Revenue, Net Income and Gross Margin of Cryo-Cell International, FY2010-FY2014
Total Assets, Total Liabilities and Asset-liability Ratio of Cryo-Cell International, FY2010-FY2014
Cord Blood Business Revenue and % of Total Revenue of Cryo-Cell International, FY2012-FY2014
Revenue, Net Income and Operating Margin of Esperite, 2009-2014
Revenue Breakdown of Esperite (by Business), 2009-2014
Revenue Structure of Esperite (by Region), 2012VS2013
Stem Cell Storage of Esperite, 2009-2014
Stem Cell Storage Revenue and EBITA of Esperite, 2009-2014
Main Subsidiaries of Zhongyuan Union Stem Cell Bioengineering as of 2014H1
Revenue and Net Income of Zhongyuan Union Stem Cell Bioengineering, 2009-2014
Revenue and Net Income of Zhongyuan Union Stem Cell Bioengineering’s Major Subsidiaries, 2012-2014
Revenue Breakdown of Zhongyuan Union Stem Cell Bioengineering (by Business), 2011-2014
Revenue Breakdown of Zhongyuan Union Stem Cell Bioengineering (by Region), 2010-2014
Gross Margin of Zhongyuan Union Stem Cell Bioengineering (by Business), 2011-2014
R&D Costs and % of Total Revenue of Zhongyuan Union Stem Cell Bioengineering, 2009-2014
Stem Cell Storage Business of Zhongyuan Union Stem Cell Bioengineering (by Type), 2009-2013
Revenue and Net Income of Zhongyuan Union Stem Cell Bioengineering, 2014-2017E
Revenue and Net Income of Golden Meditech, FY2009-FY2013
Revenue Breakdown of Golden Meditech (by Business), FY2009-FY2013
Profit Breakdown of Golden Meditech (by Business), FY2010-FY2013
Cord Blood Bank Revenue and % of Total Revenue of Golden Meditech, FY2011-FY2014
Cord Blood Bank Gross Profit and Gross Margin of Golden Meditech, FY2011-FY2014
Development Course of Golden Meditech’s Cord Blood Storage Business
Revenue and Net Income of Golden Meditech, FY2014-FY2017E
Development Course of LifeCell International
Revenue and Net Income of Cryosite, FY2011-FY2014
Revenue and EBITDA of Cryosite (by Business), FY2011-FY2014
M&A Course of NeoStem, 2009-2014
Revenue and Net Income of NeoStem, 2009-2014
Revenue Breakdown of NeoStem (by Business), 2012-2014
R&D Costs and % of Total Revenue of NeoStem, 2009-2014
Clinical Trial Projects of NeoStem, 2014
Revenue and Net Income of Mesoblast, FY2009-FY2014
R&D Costs and % of Total Revenue of Mesoblast, FY2009-FY2014
M&A Course of Mesoblast by the end of 2013
Stem Cell Product R&D Progress of Mesoblast by the end of June 2014
Revenue, Net Income and Asset-liability Ratio of MEDIPOST, FY2011-FY2013
Adult Stem Cell Drugs and Therapeutic Area of MEDIPOST
Development Course of Beike Biotechnology
Stem Cell Brands and Therapeutic Area of Osiris Therapeutics
Revenue, Net Income and Gross Margin of Osiris Therapeutics, 2011-2014
R&D Costs and % of Total Revenue of Osiris Therapeutics, 2011-2014
Revenue, Net Income and Gross Margin of Orthofix International, 2009-2014
Revenue Breakdown of Orthofix International (by Department), 2011-2014
Revenue Breakdown of Orthofix International (by Region), 2011-2013
R&D Costs and % of Total Revenue of Orthofix International, 2009-2013
Stem Cell Business Revenue of Orthofix International, 2011-2013
Revenue, Net Income and Gross Margin of Cytori Therapeutics, 2009-2014
Revenue Breakdown of Cytori Therapeutics (by Region), 2010-2014
R&D Costs and % of Total Revenue of Cytori Therapeutics, 2009-2014
Stem Cell Products R&D, Therapeutic Area and Progress of Cytori Therapeutics as of 2014H1
Revenue and Net Income of Athersys, 2009-2014
Revenue Breakdown of Athersys (by Source), 2009-2014
R&D Costs and % of Total Revenue of Athersys, 2009-2014
Stem Cell Products R&D, Therapeutic Area and Progress of Athersys as of 2014H1
Significant Cooperative Partners and Areas of Athersys
Stem Cell Products R&D, Therapeutic Area and Progress of Pluristem Therapeutics by the end of Mar. 2014
Revenue, Net Income and Gross Margin of StemCells, 2009-2014
R&D Costs and % of Total Revenue of StemCells, 2009-2014
Stem Cell Products R&D, Therapeutic Area and Progress of StemCells as of 2014H1
Revenue, Net Income and Gross Margin of ACT, 2009-2014
R&D Costs and % of Total Revenue of ACT, 2009-2014
Stem Cell Products R&D, Therapeutic Area and Progress of ACT by the end of 2013
Revenue, Net Income and Operating Margin of Celgene, 2009-2014
Cellular Therapy R&D Costs and % of Total Revenue of Celgene, 2009-2013
Stem Cell Products R&D, Therapeutic Area and Progress of Celgene as of 2014H1
Revenue, Net Income and Gross Margin of Vitro Biopharma, FY2009-FY2014
R&D Costs and % of Total Revenue of Vitro Biopharmas, 2011-2014
Stem Cell Brands and Application Fields of Vitro Biopharma
Revenue and Net Income of Celgene, FY2009-FY2013
R&D Costs and % of Total Revenue of Reneuron, 2009-2013
Stem Cell Products R&D, Therapeutic Area and Progress of Reneuron by the end of 2013
Revenue and Net Income of Tigenix, 2009-2014
Sales of Tigenix (by Region), 2011-2013
R&D Costs and % of Total Revenue of Tigenix, 2009-2014
Stem Cell Products R&D, Therapeutic Area and Progress of Tigenix as of 2014H1
Development Course of CBMG
Revenue, Net Income and Operating Margin of CBMG,2009-2014
R&D Costs and % of Total Revenue of CBMG, 2012-2014
Stem Cell Products R&D,Therapeutic Area and Progress of CBMG as of 2014H1


China Vacuum Blood Collection Industry Report, 2014-2017

The vacuum blood collection system consisting of vacuum blood collection tubes, disposable blood collection needles, tourniquets, etc transfers human venous blood to closed containers and makes it int...

China Pharmaceutical Excipients Industry Report, 2014-2017

Pharmaceutical excipients refer to adjuvants and additives used for production of pharmaceuticals and compounding of prescriptions. In addition to active ingredients, pharmaceutical excipients are als...

China Recombinant Protein Drug Industry Report, 2014-2017

The Chinese recombinant protein drug market has been expanding rapidly owing to the improvement of demand rigidity, consumption ability and the like. During 2005-2013, sales of recombinant protein dru...

China Heparin Industry Report, 2014-2017

As the world's major heparin API producer and exporter, China boasts enormous raw materials, which provides a strong support for the production of China’s heparin products. In 2013, the live pigs rais...

Global and China Monoclonal Antibody Industry Report, 2014-2019

Despite world-wide economic downturn and great changes in exchange rate, benefiting from robust market demand, global monoclonal antibody market size exceeded USD 80 billion in 2013, still one of biot...

Global and China DNA Sequencing Industry Research Report, 2014-2017

DNA sequencing is the process of reading nucleotide bases in a specific DNA molecule, that is to say determining the arrangement mode of adenine, thymine, cytosine, and guanine. It can be applied in a...

Global and China Stem Cell Industry Report, 2014-2017

Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. Stem cell therapy can be applied to treatmen...

China Human Vaccine Industry Report, 2014-2017

Vaccines can prevent and control infectious diseases, so the demand for these biological products is relatively rigid. In 2013, China’s human vaccine lot release volume grew by 4.9% from a year earlie...

China Blood Product Industry Report, 2014-2017

Plasma resource reserves and control are crucial to the development of blood products industry. Although the closure of 16 plasma collection stations in Guizhou in 2011 didn’t cause major disruption t...

China Animal Vaccine Industry Report, 2013-2016

Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. Europe and the United States and other developed countries are the main ...

China Contract Research Organization (CRO) Industry Report, 2013-2016

China CRO industry has developed rapidly in recent years, registering a CAGR of 27.2% during 2007-2013, of which the market size reached RMB 36 billion in 2013, occupying 10% of global market share. ...

Global and China Biodegradable Plastics Industry Report, 2013-2016

Global biodegradable plastic production and demand have grown rapidly in recent years, and the capacity reached 1-1.5 million t/a in 2012-2013. Among dozens of biodegradable plastic varieties develope...

Global and China Industrial Enzyme Industry Report, 2014-2016

In 2007-2013, the global industrial enzyme market size grew at the CAGR of 5.7%, reaching USD4.04 billion in 2013, 1.4 times that in 2007. The global industrial enzyme market is monopolized by a small...

China Heparin Industry Report, 2013-2015

Since the small intestines of pigs (raw materials for production of heparin) in China are abundant (the pig slaughtering volume in China approximates 50% of globe’s total) and heparin APIs are gradual...

China Lactic Acid and Derivative Industry Report, 2013

China’s lactic acid capacity and output continued to grow at the respective CAGR of 22.7% and 28.7% in 2007-2011. But limited by market demand, the annual output of most vendors was below their design...

China Human Vaccine Industry Report, 2012-2015

In the wake of China's economic growth and enhanced disease prevention awareness, Chinese human vaccine market has been expanding. In 2012, Chinese human vaccine market valued RMB10.5 billion with the...

China Blood Product Industry Report, 2012-2015

Plasma is a key raw material of the blood product industry. In August 2011, China shut down 16 plasma stations in Guizhou, resulting in a decrease of 15% in the plasma volume of the year. However, due...

China Animal Vaccine Industry Report, 2012-2015

In view of the frequent occurrence of animal epidemic diseases over the years, the Chinese government has increased investment in epidemic prevention and implemented compulsory immunization system. Be...

2005-2014 www.researchinchina.com All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号
在线客服系统